E-ISSN 2231-3206 | ISSN 2320-4672
 
2024, Vol: 14, Issue: 4
14 / 4Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Authorship Declaration

Original Research

Online Publishing Date:
27 / 06 / 2022

 


Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial

Rudra Paul, Arijit Ghosh, Nilanjan Sengupta, Pranab Kumar Sahana.


Abstract
Background: Type 2 diabetes mellitus (DM) is mainly due to multifactorial of which insulin resistance and deficiency in the incretion are two important pathophysiological factors. Vildagliptin, an oral hypoglycemic agent, acts by inhibiting dipeptidyl peptidase-4 enzyme, often uses as a first line drug along with metformin to enhance outcome.

Aim and Objective: The aim of this study was to compare the effectiveness and safety of vildagliptin 50 mg twice daily dose with vildagliptin 100 mg sustained release tablet (SR) once daily in Type 2 DM patients and uncontrolled with metformin monotherapy.

Materials and Methods: Adult patients with Type 2 DM fulfilling the inclusion criteria were randomized in two groups. Group 1 patient received metformin 1000 mg/day in two divided dose and tablet vildagliptin 50 mg 2 times daily, while Group 2 patients received metformin 1000 mg/day in two divided dose along with vildagliptin 100 mg SR once daily. Fasting plasma glucose (FPG), postprandial plasma glucose (PPPG), and glycated hemoglobin (HbA1C), were measured at baseline, on week 4, week 8, and week 12 visits. Liver function test (SGOT), SGPT, Serum Bilirubin), kidney function test electrolytes, serum urea, serum creatinine), and body weight also measured in first visit and in 12th week.

Results: HbA1C, FPG, and PPPG all three decreased equally at 12 week from their respective baseline values (P < 0.05) in both groups. There is no statistically significant alteration of liver enzymes and in serum bilirubin level from baseline to 12th week in both groups.

Conclusion: Vildagliptin 100 mg SR once daily dose is equally effective and safe as 50 mg twice daily dose in terms of reducing HbA1C, FPG, and PPPG when it is used along with metformin 1000 mg.

Key words: Vildagliptin; Type 2 Diabetes Mellitus; Efficacy


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Rudra Paul
Articles by Arijit Ghosh
Articles by Nilanjan Sengupta
Articles by Pranab Kumar Sahana
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022

Web Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. https://www.njppp.com/?mno=55832 [Access: March 14, 2024]. doi:10.5455/njppp.2022.12.062851202217862022

AMA (American Medical Association) Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. 2022; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


Vancouver/ICMJE Style

Paul R, Ghosh A, Sengupta N, Sahana PK. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol. (2022), [cited March 14, 2024]; 12(8): 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


Harvard Style

Paul, R., Ghosh, . A., Sengupta, . N. & Sahana, . P. K. (2022) Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. Natl J Physiol Pharm Pharmacol, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


Turabian Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. 2022. Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


Chicago Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. "Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial." National Journal of Physiology, Pharmacy and Pharmacology 12 (2022), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


MLA (The Modern Language Association) Style

Paul, Rudra, Arijit Ghosh, Nilanjan Sengupta, and Pranab Kumar Sahana. "Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial." National Journal of Physiology, Pharmacy and Pharmacology 12.8 (2022), 1229-1232. Print. doi:10.5455/njppp.2022.12.062851202217862022


APA (American Psychological Association) Style

Paul, R., Ghosh, . A., Sengupta, . N. & Sahana, . P. K. (2022) Comparison of efficacy and safety of vildagliptin 50 mg tablet twice daily and vildagliptin 100 mg sustained release once daily tablet on top of metformin in Indian patients with Type 2 diabetes mellitus: A randomized, open label, Phase IV parallel group, clinical trial. National Journal of Physiology, Pharmacy and Pharmacology, 12 (8), 1229-1232. doi:10.5455/njppp.2022.12.062851202217862022


Author LoginReviewer LoginAbout PublisherEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Corrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About National Journal of Physiology, Pharmacy and Pharmacology

  National Journal of Physiology, Pharmacy and Pharmacology is a monthly peer reviewed journal.  The journal is having open access polic ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Publisher

publishernjppp@gmail.com

 

Editorial query

editornjppp1@gmail.com

MOB - 8780040272